Skip to main content
. 2016 Oct 4;7(43):69231–69242. doi: 10.18632/oncotarget.12470

Figure 3. The INa-Late in control and FGF23-treated PV cardiomyocytes and the effect of ranolazine on the spontaneous beating rates of control and FGF23-treated PV cardiomyocytes.

Figure 3

A. Tracings and average data of the INa-Late from control (n = 18) and FGF23 (1 ng/mL)-treated PV cardiomyocytes (n = 18). B. An example and average data show that control (n = 8) and FGF23 (1 ng/mL)-treated PV cardiomyocytes (n = 8) after ranolazine (10 μM) had slower beating rates than those before ranolazine. * p < 0.05, *** p < 0.005.